Cooperative Agreement UG3DA062905
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $525K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Maryland, USA
Similar Awards
- This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), provides $159,615.00 to the Icahn School of Medicine at Mount Sinai for a research project titled "Predicting Craving and Relapse Using Neurobehavioral Markers of Goals and Habits in Opioid Use Disorder". The primary objectives of the research are to track daily changes in motivational control during opioid addiction treatment, and use these...
- This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $352,064 to The McLean Hospital Corporation in Belmont, MA to develop and validate a novel clinical outcome assessment measure of substance-related consequences for use in substance use disorder (SUD) treatment trials. The overarching aim is to create a patient-reported outcome measure that can serve as a valuable endpoint for SUD...
- This Project Grant award of $783,300 from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) will fund a research study titled "Informing Best Practices for Substance-Use Treatment with Real-World Evidence for People with Opioid Use Disorder and HIV (STRONG)". The study will be conducted by The Johns Hopkins University in Maryland and aims to comprehensively characterize opioid use disorder (OUD) treatment, co-occurring substance use and...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $1,445,752 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to New York University School of Medicine. The grant, titled "Characterizing Complex OUD Care Trajectories and Outcomes Following Acute Service Utilization: A Population-Based Data Linkage Study," aims to apply novel research approaches to better understand real-world opioid use disorder (OUD)...
- The U.S. National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $838,200 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Weill Medical College of Cornell University. The award, titled "JCOIN PHASE II ECONOMIC RESEARCH RESOURCE CENTER," will support the following key products and services over the award period from September 1, 2025 to May 31, 2030: Provide resources and evidence to support the...
- This $403,542 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to profile projection-specific proteome associated with the incubation of oxycodone craving. The project will focus on the orbitofrontal cortex (OFC) to dorsal striatum (DS) projections, analyzing proteome changes in OFC neuronal somas (Aim 1) and OFC-DS projection-specific synaptoneurosomes in the DS (Aim 2) during the incubation of oxycodone...
- This Cooperative Agreement award is funded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The $818,486 award will support the development and validation of the Stimulant Use Disorder Severity Scale (STUDSS), a clinical outcome assessment tool, at sites in Connecticut and California. This work aims to create a psychometrically sound measure to support medication development for...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $1,576,513 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Instanosis Inc., a woman-owned small business in Pennsylvania. The goal of this 2-year project is to develop the first FDA-cleared oral fluid fentanyl rapid test that is 10 times more sensitive, 4 times faster, and requires 10 times less oral fluid volume compared to commercially available forensic...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $591,752 Project Grant to Oprems LLC to develop a digital platform for electronic screening to identify the risk of opioid misuse and overdose. The project aims to integrate the tools and processes from Oprems' existing paper-based "ONE (Opioid and Naloxone Education)" program into a tablet-based digital platform. This digital platform will be used to consistently...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $823,809 to the University of Pittsburgh to develop and validate a suite of multidimensional measures of access to Medications for Opioid Use Disorder (MOUD) across U.S. states and the District of Columbia. The primary objectives are to: Create a Small Area Multidimensional MOUD Access (SAMMA) measure suite using public data sources. Validate and...